RVMD logo

RVMD Revolution Medicines, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$161.20
+1.77 (+1.11%)

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorect…

Market Cap: $34.87Bwww.revmed.com

Price

$207.68-1.75%
$205.57$210.76$215.96$221.15
Aug 25Sep 9

Social Signal Score

50
5d
46
5 mentions
+0.0%
30d
52
34 mentions
+0.0%
60d
51
50 mentions
+0.0%
90d
50
87 mentions
-1.8%
news: 39 · rss: 36 · marketaux: 6 · 4chan: 6

Analyst Ratings

25 analysts
Buyconsensus
Strong Buy 1Buy 22Hold 2Sell 0Strong Sell 0
Avg price target$258.28+60.2%
Low $179Median $260High $350
Current Consensus

52-week range

$40.45$221.15
Last close
$207.68
Off 52w high
-6.1%
200-day average
$135.43
vs 200-day
+53.4%

Revenue

$197.56M+1809.34%
$0.00$65.85M$131.71M$197.56M
Dec 2018Sep 2026

Analyst Estimates

FY2025
$-5.65
$-5.77–$-5.24
14 analysts
FY2026
$-8.27
$-9.52–$-7.19
18 analysts
FY2027
$-2.50
$-8.12–$0.94
19 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Mark A. Goldsmith
Sector
Healthcare
Industry
Biotechnology
Employees
883
Beta
1.43
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
9.22
www.revmed.com